mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2006-5-6-673-678mimmun-563Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESК ВОПРОСУ ОБ ИММУНОЛОГИЧЕСКИХ КРИТЕРИЯХ ЭФФЕКТИВНОСТИ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКОГО ВИРУСНОГО ГЕПАТИТА СTO THE QUESTION ABOUT IMMUNOLOGIES CRITERIAS OF EFFICIENCY OF ANTIVIRUS THERAPY OF A CHRONIC VIRUS HEPATITES CСклярЛ. Ф.SklyarL. Ph.

ул. Русская, дом 74-Б, кв. 18. Тел.: (4232) 256-444, 71-65-76

l-f-skljar@bk.ruМаркеловаЕ. В.MarkelovaE. V.l-f-skljar@bk.ruГОУ ВПО «Владивостокский государственный медицинский университет», ВладивостокRussian Federation20062307201485-6673678Copyright © Скляр Л.Ф., Маркелова Е.В., 20142014Скляр Л.Ф., Маркелова Е.В.Sklyar L.P., Markelova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/563

Резюме. Группа больных в количестве 45 человек получала стандартную комбинированную терапию препаратами рекомбинантного IFN-α в сочетании с рибавирином. Положительный эффект стандартного противовирусного лечения у больных ХВГС ассоциировался с повышением уровня IL-2, снижением уровней TNF-α, IL-1α, IL-12р40, IL-12р70 и IL-10 в периферической сыворотке. Это позволило использовать их в качестве неинвазивных маркеров устойчивого вирусологического ответа в процессе лечения хронической HCV-инфекции.

Abstract. The group of patients in amount 45 person received the standard combined therapy by preparations of recombinant IFN-α in combination with ribavirin. The positive effect of standard antivirus treatment at patients with chronic HCV-infection associated with increase of level of IL-2, decrease of levels of TNF-α, IL-1α, IL-12р40, IL-12р70 and IL-10 in peripheral serum. It has allowed to use them as noninvasive markers of the steady virologic answer during treatment of a chronic HCV-infection.

хронический вирусный гепатит Сцитокиныбиоптатыпротивовирусная комбинированная терапияchronic HCV-infectioncytokinesantivirus combined therapyReferencesНикулкина Е.Н., Крель П.Е., Лопаткина Т.Н., Игнатова Т.М. Эффективность комбинированной терапии пегинтерфероном альфа-2b (ПегИнтроном) и рибавирином (Ребетолом) первичных больных хроническим гепатитом С // Клинич. фармакология и терапия. – 2004. – Т. 13. - № 2. – С. 48-52.Никулкина Е.Н., Крель П.Е., Лопаткина Т.Н., Игнатова Т.М. Эффективность комбинированной терапии пегинтерфероном альфа-2b (ПегИнтроном) и рибавирином (Ребетолом) первичных больных хроническим гепатитом С // Клинич. фармакология и терапия. – 2004. – Т. 13. - № 2. – С. 48-52.Amaraa R., Mareckova H., Urbanek P. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis // J. Gastroenterology. 2003. – Vol. 38. - N 3. – P. 254.Amaraa R., Mareckova H., Urbanek P. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis // J. Gastroenterology. 2003. – Vol. 38. - N 3. – P. 254.Berg T., Sarrazin C., Herrmann E. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy // Hepatology. – 2003. – Vol. 37. – P. 600-609.Berg T., Sarrazin C., Herrmann E. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy // Hepatology. – 2003. – Vol. 37. – P. 600-609.Burroughs A.K. Posttransplantation prevention and treatment of recurrent hepatitis C // Liver transpl. – 2000. – Vol. 6 - N 2. – P. 35-40.Burroughs A.K. Posttransplantation prevention and treatment of recurrent hepatitis C // Liver transpl. – 2000. – Vol. 6 - N 2. – P. 35-40.Craxi A., Licata A. Clinical trial results of peginterferons in combination with ribavirin // Semin. Liver Dis. – 2003. – Vol. 23. - N 1. – P. 35-46.Craxi A., Licata A. Clinical trial results of peginterferons in combination with ribavirin // Semin. Liver Dis. – 2003. – Vol. 23. - N 1. – P. 35-46.Hadziyannis S.J., Sette ir H., Morgan T.R. Peginterferon alfa-2a and ribavirine combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirine dose // Ann. Intern. Med. – 2004. – Vol. 140. – P. 346-355.Hadziyannis S.J., Sette ir H., Morgan T.R. Peginterferon alfa-2a and ribavirine combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirine dose // Ann. Intern. Med. – 2004. – Vol. 140. – P. 346-355.Gopal D.V., Rabcin J.M., Berk B.S. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin // Liver transpl. – 2001. – N 7. – P. 181-190.Gopal D.V., Rabcin J.M., Berk B.S. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin // Liver transpl. – 2001. – N 7. – P. 181-190.McHutchison J., Gordon S.C., Schiff E.R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C // N. Engl. J. Med. – 1998. – Vol. 339. – P. 1485-1492.McHutchison J., Gordon S.C., Schiff E.R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C // N. Engl. J. Med. – 1998. – Vol. 339. – P. 1485-1492.Meurs E. Mechanisms of antiviral action of interferon // Virologie. – 1997. – Vol. 1. – P. 481-498.Meurs E. Mechanisms of antiviral action of interferon // Virologie. – 1997. – Vol. 1. – P. 481-498.National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 // Hepatology. – 2002. – Vol. 36. – P. 2-20.National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 // Hepatology. – 2002. – Vol. 36. – P. 2-20.Peters M. Action of cytokines on the immune response and viral interactions: an overview // Hepatology. – 1996. – Vol. 23. – P. 909-916.Peters M. Action of cytokines on the immune response and viral interactions: an overview // Hepatology. – 1996. – Vol. 23. – P. 909-916.Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors // Immunological reviews. – 2004. – Vol. 202. – P. 28-32.Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors // Immunological reviews. – 2004. – Vol. 202. – P. 28-32.Poynard T., McHutchison J., Manns M. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C // Gastroenterology. – 2002. – Vol. 122. – P. 1303-1313.Poynard T., McHutchison J., Manns M. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C // Gastroenterology. – 2002. – Vol. 122. – P. 1303-1313.Randall G., Rice C.M. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies // Curr. Opin. Infect. Dis. – 2001. - Vol. 14. – P.743-747.Randall G., Rice C.M. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies // Curr. Opin. Infect. Dis. – 2001. - Vol. 14. – P.743-747.Wedemeyer H., Cornberg B., Manns M.P. Immunopathogenesis and therapy of hepatitis C // Liver Immunology / M. ed Gershwin, London: Academic Press. - 2003. – Ch. 16. – P. 223-248.Wedemeyer H., Cornberg B., Manns M.P. Immunopathogenesis and therapy of hepatitis C // Liver Immunology / M. ed Gershwin, London: Academic Press. - 2003. – Ch. 16. – P. 223-248.

The authors declare that there are no conflicts of interest present.